Fabinshy Thangarajah1, Insa Enninga2, Wolfram Malter3, Stefanie Hamacher4, Birgid Markiefka5, Lisa Richters2, Stefan Krämer6, Peter Mallmann2, Verena Kirn2,3. 1. Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany Fabinshy.Thangarajah@uk-koeln.de. 2. Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany. 3. Breast Center, University Hospital of Cologne, Cologne, Germany. 4. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany. 5. Department of Pathology, University Hospital of Cologne, Cologne, Germany. 6. Breast Center, Helios Clinic Krefeld, Krefeld, Germany.
Abstract
BACKGROUND/AIM: The Ki-67 index is chiefly important for distinguishing between luminal A and luminal B human epidermal growth factor receptor 2 (HER2neu)-negative breast cancer subtypes. However, its ability to predict response to chemotherapy is uncertain. PATIENTS AND METHODS: Patients treated for primary breast cancer at the University Hospital of Cologne were identified. Immunohistochemistry for Ki-67 detection was performed according to standard protocols. Kaplan-Meier survival curves were calculated and compared using the log-rank test. RESULTS: Patients with low Ki-67 index had a significantly better disease-free-survival (DFS) than patients with high Ki-67 index (hazard ratio=2.85; 95% confidence interval=1.45-5.59; p=0.002). A significant influence on DFS was demonstrated (hazard ratio(HR)=1.02; confidence interval(CI)=1.00-1.04; p=0.048) within the subgroup of hormone receptor-positive and HER2neu-negative patients, but not within the subgroup of those with luminal B/HER2neu-negative tumors (DFS: p=0.801; overall-survival: p=0.379). CONCLUSION: The Ki-67 index has a prognostic impact on DFS in patients with hormone receptor-positive and HER2neu-negative tumors. The strict cut-off value was not suitable for distinguishing between high- and low-risk patients and their response to adjuvant chemotherapy. Copyright
BACKGROUND/AIM: The Ki-67 index is chiefly important for distinguishing between luminal A and luminal B humanepidermal growth factor receptor 2 (HER2neu)-negative breast cancer subtypes. However, its ability to predict response to chemotherapy is uncertain. PATIENTS AND METHODS: Patients treated for primary breast cancer at the University Hospital of Cologne were identified. Immunohistochemistry for Ki-67 detection was performed according to standard protocols. Kaplan-Meier survival curves were calculated and compared using the log-rank test. RESULTS:Patients with low Ki-67 index had a significantly better disease-free-survival (DFS) than patients with high Ki-67 index (hazard ratio=2.85; 95% confidence interval=1.45-5.59; p=0.002). A significant influence on DFS was demonstrated (hazard ratio(HR)=1.02; confidence interval(CI)=1.00-1.04; p=0.048) within the subgroup of hormone receptor-positive and HER2neu-negative patients, but not within the subgroup of those with luminal B/HER2neu-negative tumors (DFS: p=0.801; overall-survival: p=0.379). CONCLUSION: The Ki-67 index has a prognostic impact on DFS in patients with hormone receptor-positive and HER2neu-negative tumors. The strict cut-off value was not suitable for distinguishing between high- and low-risk patients and their response to adjuvant chemotherapy. Copyright
Authors: George S Stoyanov; Deyan Dzhenkov; Peter Ghenev; Bogomil Iliev; Yavor Enchev; Anton B Tonchev Journal: Med Oncol Date: 2018-01-31 Impact factor: 3.064
Authors: Okechinyere J Achilonu; Elvira Singh; Gideon Nimako; René M J C Eijkemans; Eustasius Musenge Journal: Biomed Res Int Date: 2022-01-20 Impact factor: 3.411